Evidence map›Paper›PMID 39218946›Full record

ArticleStem cell research & therapy2024

Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.

Xiaoke Jiang, Xiaoying Luo, Conghui Cai, Yangqiu Bai, Hui Ding, Han Yue, Yalong Li, Zhiyu Yang, Huimin Zhang, Yuan Liang and 8 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. NINJ1 impairs the anti-inflammatory function of hUC-MSCs with synergistic IFN-γ and TNF-α stimulation.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2025
    Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiaoke Jiang *Department of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Xiaoying Luo *Department of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Conghui Cai *Department of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Yangqiu BaiDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Hui DingDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Han YueStem Cell Research Center, Henan Key Laboratory of Stem Cell Differentiation and Modification, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Yalong LiStem Cell Research Center, Henan Key Laboratory of Stem Cell Differentiation and Modification, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Zhiyu YangDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Huimin ZhangDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Yuan LiangDepartment of Pulmonary and Critical Care Medicine, Xinyang Central Hospital, No.1, Siyi Road, Xinyang, Henan Province, 464000, China.
Cong PengDepartment of Gastroenterology, Yunfu People's Hospital, No. 120, Huanshi East Road, Yunfu, Guangdong Province, 527300, China.
Huanrong HuangDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Min LiuDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Zhenjuan LiDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Yujie ShiDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China.
Shuangyin HanDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China. hansy007@zzu.edu.cn.
Xiuling LiDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China. zzlixiuling@aliyun.com.
Bingyong ZhangDepartment of Gastroenterology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, School of Clinical Medicine, Henan University, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China. zhbingyong@sina.com.ORCID 0000-0003-3515-9954

Funding

medical science and technology project of Henan Province SBGJ202001002National Health Commission project CMR-20180615-1001Science and Technology Department of Henan Province 212102310203
6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.

methodsThis prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10

resultsForty-one patients were enrolled and received UMSC therapy. At 2 months, 73.2% (30/41) of patients achieved a clinical response, and 41.5% (17/41) achieved a clinical remission. At 6 months, 2 patients were lost to follow-up; the corresponding figures were 70.0% (25/41) and 34.2% (14/41), respectively. After UMSC therapy, the Mayo score, Mayo endoscopy score, mean and maximum values of Ulcerative Colitis Endoscopic Index of Severity and Nancy index were significantly reduced compared with baseline values. Additionally, the levels of progerin and inflammatory markers, such as interleukin (IL)-1β, IL-6, IL-8, IL-12, and IL-17 A decreased, while hemoglobin, albumin, and IL-10/IL-17 A ratio increased, particularly in the response group. Multiple stepwise logistic regression analysis showed age was an independent risk factor affecting efficacy (odds ratio, 0.875 (95% confidence interval (0.787, 0.972)); the area under the receiver operating characteristic curve for age was 0.79. No serious adverse events were observed during or after UMSC therapy.

conclusionUMSCs are safe and effective for patients with UC, with age being an independent risk factor affecting efficacy. Mechanistically, UMSC treatment may ameliorate cell senescence and suppress the secretion of pro-inflammatory cytokines.

trial registrationThe study was retrospectively registered at www.chictr.org.cn/ (ChiCTR1900026035) on September 18, 2019.

Indexed as

Colitis, UlcerativeMesenchymal Stem CellsMesenchymal Stem Cell TransplantationUmbilical CordAdultCytokinesFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeCytokinesAgingInflammationUlcerative colitisUmbilical cord mesenchymal stem cells

Identifiers

PMID39218946
PMCPMC11368034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.